• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐药结核病的治疗。

Treatment of drug-resistant tuberculosis.

机构信息

Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, Montreal, QC, Canada;

出版信息

Infect Drug Resist. 2011;4:129-35. doi: 10.2147/IDR.S10332. Epub 2011 Jul 21.

DOI:10.2147/IDR.S10332
PMID:21904458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3163983/
Abstract

CLINICAL QUESTION

What is the best approach to the treatment of drug-resistant tuberculosis (TB)?

RESULTS

Evidence-based treatment of drug-susceptible TB is the best means of preventing the development of drug-resistant disease. Suspecting the possibility of drug-resistant TB, and prompt detection of all forms of drug-resistant TB, not only multidrug-resistant and extensively drug-resistant TB, should be part of the algorithm for diagnosis and management of all patients with active TB.

IMPLEMENTATION

Treatment of all forms of drug-resistant TB must be tailored to the specific form of resistance with appropriate and effective drug regimens.

摘要

临床问题

治疗耐药结核病(TB)的最佳方法是什么?

结果

基于证据的敏感结核病治疗是预防耐药性疾病发展的最佳手段。怀疑耐药性结核病的可能性,并及时发现所有形式的耐药性结核病,不仅是耐多药和广泛耐药性结核病,都应成为所有活动性结核病患者诊断和管理算法的一部分。

实施

必须针对特定的耐药形式,采用适当和有效的药物方案,对所有形式的耐药性结核病进行治疗。

相似文献

1
Treatment of drug-resistant tuberculosis.耐药结核病的治疗。
Infect Drug Resist. 2011;4:129-35. doi: 10.2147/IDR.S10332. Epub 2011 Jul 21.
2
Tuberculosis结核病
3
Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.耐多药结核病和广泛耐药结核病的管理:现状与未来展望
Kekkaku. 2011 Jan;86(1):9-16.
4
Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.2007 年至 2013 年中国耐多药结核分枝杆菌分离株中莫西沙星耐药率的大幅增加。
Microbiol Spectr. 2021 Dec 22;9(3):e0040921. doi: 10.1128/Spectrum.00409-21. Epub 2021 Dec 1.
5
Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.韩国耐多药结核病患者的额外耐药模式:对治疗方案设计的启示
J Korean Med Sci. 2017 Apr;32(4):636-641. doi: 10.3346/jkms.2017.32.4.636.
6
Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.俄罗斯巴什科尔托斯坦地区耐多药结核病的治疗效果:一项回顾性队列研究。
Int J Infect Dis. 2019 Apr;81:203-209. doi: 10.1016/j.ijid.2019.02.010. Epub 2019 Feb 19.
7
Antibiotic resistance acquisition versus primary transmission in the presentation of extensively drug-resistant tuberculosis.广泛耐药结核病发病时的耐药性获得与原发性传播。
Int J Mycobacteriol. 2022 Oct-Dec;11(4):343-348. doi: 10.4103/ijmy.ijmy_187_22.
8
Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.贝达喹啉治疗南非耐多药结核病患者的安全性、疗效、利用情况和耐药性的出现:一项回顾性队列分析。
BMC Infect Dis. 2022 Nov 21;22(1):870. doi: 10.1186/s12879-022-07861-x.
9
Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.耐多药结核病和广泛耐药结核病的管理:2012 年更新。
Respirology. 2013 Jan;18(1):8-21. doi: 10.1111/j.1440-1843.2012.02257.x.
10
The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study.提高对异烟肼耐药结核病的检测和治疗水平对耐多药结核病流行率的影响:建模研究。
PLoS One. 2019 Jan 24;14(1):e0211355. doi: 10.1371/journal.pone.0211355. eCollection 2019.

引用本文的文献

1
Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.靶向巨噬细胞治疗结核病的药物递送最新进展
Adv Ther (Weinh). 2022 Jun;5(6). doi: 10.1002/adtp.202100193. Epub 2022 Mar 9.
2
Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications.控制印度的耐药结核病疫情:挑战与影响。
Epidemiol Health. 2021;43:e2021022. doi: 10.4178/epih.e2021022. Epub 2021 Apr 7.
3
Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study.柬埔寨对二线抗结核药物的耐药性:一项表型与基因研究。
Infect Drug Resist. 2021 Mar 17;14:1089-1104. doi: 10.2147/IDR.S289907. eCollection 2021.
4
Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future.耐多药结核病个体化治疗方案的优势与挑战:意大利终止结核病组织展望未来
Infect Drug Resist. 2020 Aug 11;13:2795-2800. doi: 10.2147/IDR.S257480. eCollection 2020.
5
Bazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy.巴泽多昔芬通过增强自噬来抑制细胞内结核分枝杆菌的生长。
mSphere. 2020 Apr 8;5(2):e00124-20. doi: 10.1128/mSphere.00124-20.
6
AtbPpred: A Robust Sequence-Based Prediction of Anti-Tubercular Peptides Using Extremely Randomized Trees.AtbPpred:使用极端随机树对抗结核肽进行基于序列的稳健预测。
Comput Struct Biotechnol J. 2019 Jul 3;17:972-981. doi: 10.1016/j.csbj.2019.06.024. eCollection 2019.
7
In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D.与结核分枝杆菌RpoB突变H526D相关的体外和体内适应性代价。
Future Microbiol. 2017 Jul;12(9):753-765. doi: 10.2217/fmb-2017-0022. Epub 2017 Mar 27.
8
Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010.异烟肼单耐药结核病:对1995 - 2010年墨西哥南部肺结核患者治疗结果及生存情况的影响
PLoS One. 2016 Dec 28;11(12):e0168955. doi: 10.1371/journal.pone.0168955. eCollection 2016.
9
Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) Antibiotics.耐药机制与细菌烯酰-酰基载体蛋白还原酶(FabI)抗生素的未来
Cold Spring Harb Perspect Med. 2016 Mar 1;6(3):a027045. doi: 10.1101/cshperspect.a027045.
10
A prospective study of tuberculosis drug susceptibility in sabah, malaysia, and an algorithm for management of isoniazid resistance.马来西亚沙巴州结核病药物敏感性的前瞻性研究和异烟肼耐药的管理算法。
J Trop Med. 2015;2015:261925. doi: 10.1155/2015/261925. Epub 2015 Mar 9.

本文引用的文献

1
Global survey of national tuberculosis drug policies.全球国家结核病药物政策调查。
Int J Tuberc Lung Dis. 2011 May;15(5):613-9. doi: 10.5588/ijtld.10.0199.
2
Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.耐多药和广泛耐药结核病患者家庭中的结核病负担:一项回顾性队列研究。
Lancet. 2011 Jan 8;377(9760):147-52. doi: 10.1016/S0140-6736(10)61972-1. Epub 2010 Dec 8.
3
Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?印度孟买私人执业医生的结核病管理:二十年来有何变化?
PLoS One. 2010 Aug 9;5(8):e12023. doi: 10.1371/journal.pone.0012023.
4
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.肺结核治疗期间痰液监测对预测结局的作用:系统评价和荟萃分析。
Lancet Infect Dis. 2010 Jun;10(6):387-94. doi: 10.1016/S1473-3099(10)70071-2.
5
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis.标准化治疗活动性肺结核预测结局和耐药性。
Eur Respir J. 2010 Oct;36(4):870-7. doi: 10.1183/09031936.00151709. Epub 2010 Mar 29.
6
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.标准化治疗既往治疗和/或耐异烟肼单药的活动性肺结核患者:系统评价和荟萃分析。
PLoS Med. 2009 Sep;6(9):e1000150. doi: 10.1371/journal.pmed.1000150.
7
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.6 个月与 9 个月间歇性治疗方案在结核分枝杆菌感染的 HIV 患者中的疗效:一项随机临床试验。
Am J Respir Crit Care Med. 2010 Apr 1;181(7):743-51. doi: 10.1164/rccm.200903-0439OC. Epub 2009 Dec 3.
8
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.利福平持续时间和间歇性对结核病治疗结果的影响:一项系统评价和荟萃分析。
PLoS Med. 2009 Sep;6(9):e1000146. doi: 10.1371/journal.pmed.1000146. Epub 2009 Sep 15.
9
Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.耐多药结核病的治疗结局:系统评价和荟萃分析。
PLoS One. 2009 Sep 9;4(9):e6914. doi: 10.1371/journal.pone.0006914.
10
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.在肺结核强化期治疗中用莫西沙星替代异烟肼。
Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.